Garcinia Cambogia is one such example. Marketed as a weight-loss pill, it has had an exponential rise in sales since it was featured on the Doctor Oz show.
Garcinia cambogia is the former scientific name of a native Southeast Asian plant, belonging to the family Clusiaceae, that bears a pumpkin-shaped fruit. The skin of the fruit contains the active ingredient, hydroxycitric acid (HCA). HCA inhibits an enzyme that produces fatty acid, thus suppressing fatty acid and the processing of cholesterol.
But does this mode of action translate to the weight-loss claims associated with it? Or is it just clever marketing convincing us this product helps us lose weight?
Double-blinded, randomised controlled trials are the gold standard of clinical study and whenever possible should be conducted to test the effectiveness of a treatment compared to a placebo. Weight-loss products should be assessed for a minimum of six months, with a further six-month follow-up period (12 months total).
In fact, the majority of well-designed trials investigating the effect of this product on weight loss have found no effect that is of clinical relevance. In a 12-week double-blind, placebo-controlled trial conducted in humans, people receiving 3000mg of Garcinia Cambogia extract (1500mg of the active component HCA) per day lost the same amount of weight as the control group.
Another 12-week study with a four-week follow-up (16 weeks total) also found no greater weight-loss effect than for a placebo control group. For those studies where a statistically significant effect was reported, the weight loss was around one kilogram more than for those receiving a placebo pill.
Some complementary medicines have been found to contribute to improved health outcomes, through increased efficacy and cost-effectiveness. However, if there is to be a role for such complementary and alternative weight-loss products and medicines, we must build upon the evidence to investigate whether these increasingly popular products are a viable treatment option.
A recent Obesity Australia and Price Waterhouse Coopers report found obesity cost Australia A$8.6 billion in 2011-2012, with the indirect costs far higher. We must establish whether complementary medicines have a role to play in preventing and treating obesity. If we take no action to reduce obesity rates, an additional 2.4 million people will become obese at a cost of $87.7 billion over 10 years.